文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

危重症患者液体平衡控制:POINCARE-2 阶梯楔形整群随机试验结果

Fluid balance control in critically ill patients: results from POINCARE-2 stepped wedge cluster-randomized trial.
PubMed 文献 · Crit Care · 2023-02-21
一句话结论POINCARE-2 保守液体管理策略未降低危重症机械通气患者60天死亡率(30.5% vs 33.9%,p=0.26),但高钠血症更常见(5.3% vs 2.3%,p=0.01)。

POINCARE-2 为阶梯楔形整群开放标签随机对照试验,纳入法国9家医院12个ICU中≥18岁、机械通气、入ICU>48且≤72小时、预计入住>24小时的危重症患者。策略组自入ICU第2至14天实施每日体重驱动的液体入量限制、利尿剂及肾脏替代治疗时超滤。主要终点60天全因死亡率在策略组与对照组间无差异(30.5%,95%CI 26.2-34.8 vs 33.9%,95%CI 29.6-38.2,p=0.26)。安全性结局中仅高钠血症在策略组更频繁(5.3% vs 2.3%,p=0.01)。作者认为该策略未降低死亡率,但因开放标签和阶梯楔形设计,意向性分析可能未反映实际暴露,完全放弃该策略前可能需要进一步分析。

要点

  • 策略组60天死亡率30.5%(95%CI 26.2-34.8)vs 对照组33.9%(95%CI 29.6-38.2),p=0.26,无显著差异。
  • 高钠血症在策略组更常见(5.3% vs 2.3%,p=0.01),是唯一显著增加的安全性事件。
  • 策略为入ICU第2至14天每日体重驱动的液体入量限制、利尿剂及肾脏替代治疗时超滤。
  • 意向性分析(CRA)纳入策略组433例、对照组472例;随机前后分析(RBAA)策略组643例、对照组718例,结果相似。
  • 作者认为因开放标签和阶梯楔形设计,意向性分析可能未反映实际暴露,完全放弃该策略前可能需要进一步分析。

适用人群与场景

  • ≥18岁、机械通气、入ICU>48且≤72小时、预计入组后入住ICU>24小时的危重症患者。
  • 招募自法国9家医院12个志愿ICU,2016年5月至2019年5月。

诊断标准与关键阈值

  • 纳入标准:≥18岁,机械通气,入ICU>48且≤72小时,预计入组后入住时间>24小时。

处置流程与药物剂量

  • POINCARE-2策略:入ICU第2天至第14天,每日体重驱动的液体入量限制、利尿剂给药、肾脏替代治疗时超滤。

研究设计与关键结果

  • 设计:阶梯楔形整群开放标签随机对照试验,意向性分析包括整群随机分析(CRA)和随机前后分析(RBAA)。
  • 筛查10272例,1361例符合纳入标准,1353例完成随访。
  • CRA中策略组433例、对照组472例;RBAA中策略组643例、对照组718例。
  • CRA中策略组平均(SD)年龄63.7(14.1)岁 vs 对照组65.7(14.3)岁;入ICU平均(SD)体重78.5(20.0)kg vs 79.4(23.5)kg。
  • 策略组129例死亡、对照组160例死亡。
  • 60天死亡率:策略组30.5%(95%CI 26.2-34.8)vs 对照组33.9%(95%CI 29.6-38.2),p=0.26。
  • 安全性结局中仅高钠血症在策略组更频繁(5.3% vs 2.3%,p=0.01)。
  • RBAA结果与CRA相似。

证据类型、等级与局限

  • 证据类型:阶梯楔形整群随机对照试验(开放标签)。
  • 局限:作者指出因开放标签和阶梯楔形设计,意向性分析可能未反映实际暴露;完全放弃该策略前可能需要进一步分析。

对床旁实践的改变

  • 作者认为POINCARE-2保守液体管理策略未降低危重症患者死亡率。
  • 作者认为因开放标签和阶梯楔形设计,意向性分析可能未反映实际暴露,进一步分析前不应完全放弃该策略。

指南或共识出处

  • POINCARE-2试验,注册于ClinicalTrials.gov(NCT02765009),注册日期2016年4月29日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In critically ill patients, positive fluid balance is associated with excessive mortality. The POINCARE-2 trial aimed to assess the effectiveness of a fluid balance control strategy on mortality in critically ill patients.

METHODS: POINCARE-2 was a stepped wedge cluster open-label randomized controlled trial. We recruited critically ill patients in twelve volunteering intensive care units from nine French hospitals. Eligible patients were ≥ 18 years old, under mechanical ventilation, admitted to one of the 12 recruiting units for > 48 and ≤ 72 h, and had an expected length of stay after inclusion > 24 h. Recruitment started on May 2016 and ended on May 2019. Of 10,272 patients screened, 1361 met the inclusion criteria and 1353 completed follow-up. The POINCARE-2 strategy consisted of a daily weight-driven restriction of fluid intake, diuretics administration, and ultrafiltration in case of renal replacement therapy between Day 2 and Day 14 after admission. The primary outcome was 60-day all-cause mortality. We considered intention-to-treat analyses in cluster-randomized analyses (CRA) and in randomized before-and-after analyses (RBAA).

RESULTS: A total of 433 (643) patients in the strategy group and 472 (718) in the control group were included in the CRA (RBAA). In the CRA, mean (SD) age was 63.7 (14.1) versus 65.7 (14.3) years, and mean (SD) weight at admission was 78.5 (20.0) versus 79.4 (23.5) kg. A total of 129 (160) patients died in the strategy (control) group. Sixty-day mortality did not differ between groups [30.5%, 95% confidence interval (CI) 26.2-34.8 vs. 33.9%, 95% CI 29.6-38.2, p = 0.26]. Among safety outcomes, only hypernatremia was more frequent in the strategy group (5.3% vs. 2.3%, p = 0.01). The RBAA led to similar results.

CONCLUSION: The POINCARE-2 conservative strategy did not reduce mortality in critically ill patients. However, due to open-label and stepped wedge design, intention-to-treat analyses might not reflect actual exposure to this strategy, and further analyses might be required before completely discarding it. Trial registration POINCARE-2 trial was registered at ClinicalTrials.gov (NCT02765009). Registered 29 April 2016.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bollaert PE, Monnier A, Schneider F, et al. Fluid balance control in critically ill patients: results from POINCARE-2 stepped wedge cluster-randomized trial. Crit Care. 2023. PMID: 36810101. doi:10.1186/s13054-023-04357-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。